ObjectiveTo assess the feasibility of the unrestricted and unlabeled use of blood drawn therapeutically from patients with hereditary hemochromatosis (HH) in the United States, via a review of the scientific literature, current media reports, and governmental regulations.
No takes yet. Share an insight, caveat, or question.
Tan et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: